amerisourcebergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain and enhance patient care. as the leader in global sourcing and distribution, we source and distribute brand, generic, specialty, otc pharmaceuticals and other healthcare products. we increase the effectiveness and efficiency of your supply chain by ensuring products are delivered securely, consistently and cost-effectively, improving product access for pharmacies, providers and patients. our pharmacy solutions result in greater operational efficiency, cost control, growth opportunities and patient safety. our provider solutions drive operational efficiency, financial performance and improve quality of care. our manufacturer solutions maximize success at every stage of the product lifecycle. amerisourcebergen. where knowledge, reach and partnership shape healthcare delivery.
Company profile
Ticker
COR
Exchange
Website
CEO
Steven Collis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERISOURCE BERGEN CORP, AMERISOURCEBERGEN CORP
SEC CIK
Corporate docs
Subsidiaries
AB Singapore Investments Pte Ltd • AB UK Holdings Ltd • AH UK Holdco 1 Ltd • Amerisource Receivables Financial Corporation • AmerisourceBergen Drug Corporation • AmerisourceBergen Global Holdings GmbH • AmerisourceBergen Global Manufacturer Services GmbH • AmerisourceBergen Group GmbH • AmerisourceBergen International B.V. • AmerisourceBergen International Holdings Inc. ...
IRS number
233079390
COR stock data
Latest filings (excl ownership)
8-K/A
Departure of Directors or Certain Officers
15 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
8-K
Cencora Announces Leadership Succession Plan
12 Mar 24
8-K
1.05
27 Feb 24
8-K
Entry into a Material Definitive Agreement
9 Feb 24
8-K
Cencora Closes $500 Million Senior Notes Offering
7 Feb 24
424B2
Prospectus for primary offering
7 Feb 24
8-K
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
7 Feb 24
FWP
Free writing prospectus
5 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
Transcripts
COR
Earnings call transcript
2023 Q3
2 Aug 23
COR
Earnings call transcript
2023 Q2
2 May 23
COR
Earnings call transcript
2023 Q1
1 Feb 23
COR
Earnings call transcript
2022 Q3
3 Nov 22
COR
Earnings call transcript
2022 Q3
3 Aug 22
COR
Earnings call transcript
2022 Q2
4 May 22
COR
Earnings call transcript
2022 Q1
2 Feb 22
COR
Earnings call transcript
2021 Q4
4 Nov 21
COR
Earnings call transcript
2021 Q2
5 May 21
COR
Earnings call transcript
2021 Q1
4 Feb 21
Latest ownership filings
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
Lorence H. Kim
13 Mar 24
4
Silvana Battaglia
13 Mar 24
4
James F Cleary
13 Mar 24
4
Elizabeth S Campbell
13 Mar 24
4
DERMOT MARK DURCAN
13 Mar 24
4
RICHARD W GOCHNAUER
13 Mar 24
4
KATHLEEN W HYLE
13 Mar 24
4
LON R GREENBERG
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.75 bn | 2.75 bn | 2.75 bn | 2.75 bn | 2.75 bn | 2.75 bn |
Cash burn (monthly) | (no burn) | 70.05 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 394.89 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 2.36 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 33.7 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
74.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 842 |
Opened positions | 145 |
Closed positions | 249 |
Increased positions | 264 |
Reduced positions | 315 |
13F shares | Current |
---|---|
Total value | 19.81 tn |
Total shares | 148.98 mm |
Total puts | 2.73 mm |
Total calls | 3.12 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
WBA Walgreens Boots Alliance | 30.49 mm | $6.00 bn |
Vanguard | 20.51 mm | $4.21 tn |
T. Rowe Price | 10.71 mm | $2.20 bn |
STT State Street | 7.90 mm | $1.62 tn |
JPM JPMorgan Chase & Co. | 5.46 mm | $1.12 tn |
FMR | 4.62 mm | $949.69 bn |
Boston Partners | 4.03 mm | $829.40 bn |
Wellington Management | 3.81 mm | $782.10 bn |
Bessemer | 3.15 mm | $646.94 mm |
MS Morgan Stanley | 2.79 mm | $573.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Werner Baumann | Common Stock | Grant | Acquire A | No | No | 0 | 843 | 0.00 | 1,563 |
12 Mar 24 | Lon R Greenberg | Common Stock | Grant | Acquire A | No | No | 0 | 843 | 0.00 | 27,062 |
12 Mar 24 | Lorence H. Kim | Common Stock | Grant | Acquire A | No | No | 0 | 843 | 0.00 | 2,735 |
12 Mar 24 | Redonda Miller | Common Stock | Grant | Acquire A | No | No | 0 | 843 | 0.00 | 2,405 |
12 Mar 24 | Tyler Lauren M | Common Stock | Grant | Acquire A | No | No | 0 | 843 | 0.00 | 1,563 |
News
Here's How Much $100 Invested In Cencora 10 Years Ago Would Be Worth Today
13 Mar 24
Cencora CEO Steven H. Collis To Transition To Executive Chair; COO Robert P. Mauch To Become President And CEO, Both Appointments Effective October 1, 2024; Reaffirms FY24 Guidance
12 Mar 24
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
28 Feb 24
Critical Insights From Cencora Analyst Ratings: What You Need To Know
26 Feb 24
Leerink Partners Initiates Coverage On Cencora with Outperform Rating, Announces Price Target of $261
26 Feb 24
Press releases
Cencora Announces Leadership Succession Plan
12 Mar 24
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
7 Feb 24
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
7 Feb 24
Cencora Closes $500 Million Senior Notes Offering
7 Feb 24
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
5 Feb 24